Loading
Pediatric Health and Respiratory Diseases / Pneumonia and Respiratory Infections · Journal article
Erj Open Research · August 6, 2026
Early or partial results. Treat as a signal, not a conclusion.
PRESIDE is a planned international prospective observational registry designed to characterise the prevalence and burden of antimicrobial resistance in chronic lung disease patients. This is a protocol announcement with no primary data or results; its value will depend on recruitment success, data quality, and eventual publication of epidemiological findings.
Prospective observational registry. Paediatric and adult patients with chronic lung disease who have undergone respiratory microbiological testing as part of routine clinical care within the year prior to data collection.. Global, multicentre study; specific centres and countries not listed in protocol..
Registry to recruit both paediatric and adult patients with CLD who have undergone respiratory microbiological testing within the year prior to data collection Enrolment via two-week recruitment periods held twice yearly over five years from 2025 to 2030 Captures demographics, smoking history, CLD type and aetiology, microbiological history, comorbidities, clinical characteristics, therapeutic exposures, and respiratory microbiology results
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
Clinicians and researchers should view this as an emerging data source that, once results are published, may provide robust real-world epidemiological evidence on AMR prevalence in chronic respiratory infections and inform stewardship and guideline development. Until data are available, this protocol cannot guide practice.
This is a registry protocol describing planned prospective data collection with no results reported; it represents a study design and feasibility framework rather than evidence of efficacy or epidemiological findings.
As stated by the source record.
Quoted from the source exactly as published.
Clinicians and researchers should view this as an emerging data source that, once results are published, may provide robust real-world epidemiological evidence on AMR prevalence in chronic respiratory infections and inform stewardship and guideline development. Until data are available, this protocol cannot guide practice.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
Antimicrobial resistance (AMR) is an escalating global health threat. Chronic lung diseases (CLDs) represent a key area in which AMR poses unique and often underestimated challenges, yet high-quality epidemiological data remain scarce. To address this gap, the European Respiratory Society Clinical Research Collaboration on AMR in Lung Infections (AMR-Lung CRC) has developed PRESIDE, an international prospective observational registry designed to evaluate the prevalence and burden of AMR in patients with CLD. PRESIDE is a global, multicentre study recruiting paediatrics and adults with CLD who have undergone respiratory microbiological testing as part of routine clinical care within the year prior to data collection. Participating centres enroll patients during two-week recruitment periods, held twice yearly over five years from 2025 to 2030. The registry captures a comprehensive set of core variables, including demographics and smoking history, CLD type and aetiology, microbiological history, comorbidities, clinical characteristics, therapeutic exposures, and respiratory microbiology results. This registry aims to generate robust, prospective, real-world evidence on AMR epidemiology in CLD, enabling comparison across regions and disease phenotypes. Findings are expected to inform clinical decision-making, support antimicrobial stewardship, and guide the development of context-specific guidelines and public health strategies. Ultimately, PRESIDE seeks to strengthen global efforts to address AMR in chronic respiratory infections and improve outcomes for patients with CLD.
Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.